Table 3.
Changes in biomarker measurements over time for cases and controls
| Cases | Controls | Case-controls | ||||
|---|---|---|---|---|---|---|
| Slope (95% CI) | p | Slope (95% CI) | p | Difference (95% CI) | p | |
| pNGAL (ng/ml) | 15.38 (3.30, 27.46) | 0.01* | −2.44 (−14.23, 9.35) | 0.68 | 17.82 (0.91, 34.73) | 0.04* |
| pIL-18 (pg/ml) | −14.25 (−31.69, 3.19) | 0.11 | −6.83 (−24.01, 10.35) | 0.43 | −7.42 (−31.94, 17.10) | 0.54 |
| pL-FABP (ng/ml) | 3.16 (−3.49, 9.82) | 0.34 | −0.96 (−7.26, 5.34) | 0.76 | 4.12 (−5.06, 13.31) | 0.37 |
| uNGAL (ng/ml) | −60.35 (−199.92, 79.22) | 0.39 | 32.14 (−98.88, 163.16) | 0.62 | −92.49 (−284.35, 99.37) | 0.33 |
| uIL-18 (pg/ml) | −2.28 (−8.54, 3.99) | 0.47 | 2.40 (−3.51, 8.30) | 0.42 | −4.67 (−13.30, 3.96) | 0.28 |
| uL-FABP (ng/ml) | 6.70 (2.31, 11.10) | <0.01* | 0.68 (−3.60, 4.95) | 0.75 | 6.03 (−0.13, 12.18) | 0.05 |
| uNGAL/Cr (ng/ml per mg/dl) | 0.86 (−3.15, 4.87) | 0.67 | 0.73 (−3.10, 4.56) | 0.70 | 0.13 (−5.43, 5.69) | 0.96 |
| uIL-18/Cr (pg/ml per mg/dl) | −0.24 (−0.57, 0.09) | 0.14 | 0.07 (−0.24, 0.37) | 0.66 | −0.31 (−0.75, 0.14) | 0.17 |
| uL-FABP/Cr (ng/ml per mg/dl) | 0.20 (0.06, 0.34) | 0.01* | −0.03 (−0.17, 0.11) | 0.71 | 0.23 (0.02, 0.43) | 0.03* |
| GFR (ml/min per 1.73m2) | −4.02 (−4.93, −3.11) | < 0.0001* | −0.61 (−1.57, 0.36) | 0.21 | −3.42 (−4.73, −2.10) | < 0.0001* |
All statistics estimated from linear mixed effects models
Confidence interval (CI), plasma (p), urine (u), neutrophil gelatinase-associated lipocalin (NGAL) interleukin 18 (IL-18), liver-type fatty acid binding protein (L-FABP), creatinine (Cr), glomerular filtration rate (GFR)
*
Clinical significance (p < 0.05)